Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.65 |
| ▸ | CA1 | P00915 | 5/20 | 0.65 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447634 | 1.00 | CA2 (0.65) | CA2CA1CTRB1CA12CA9 | |
| SCHEMBL989156 | 1.00 | CA2 (0.65) | CA2CA1CTRB1CA12CA9 | |
| Ethylenediamine SCHEMBL2476802 | 0.93 | CA2 (0.62) | CA2CA1CTRB1CA12CA9 | |
| SCHEMBL18979294 | 0.91 | CA2 (0.64) | CA2CA1CTRB1CA12CA9 | |
| Trifluoroacetic Acid SCHEMBL29652104 | 0.91 | CA2 (0.56) | CA2CA1CTRB1CA12CA9 | |
| SCHEMBL12636075 | 0.89 | CA1 (0.57) | CA2CA1CTRB1CA12CA9 | |
| SCHEMBL12574366 | 0.89 | CA1 (0.57) | CA2CA1CTRB1CA12CA9 | |
| SCHEMBL24945573 | 0.86 | CTRB1 (0.55) | CA2CA1CTRB1CA12CA9 | |
| SCHEMBL2330376 | 0.86 | CTRB1 (0.51) | CA2CA1CTRB1ACEPTPN1 | |
| SCHEMBL24945572 | 0.86 | CTRB1 (0.55) | CA2CA1CTRB1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114377214-A | Injectable sodium alginate hydrogel for assisting EMR or ESD operation | 南京工业大学 | 2022-04-22 | — | — | CN | claimed |
| US-9410000-B2 | Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels | UNIVERSITA' DEGLI STUDI DI PALERMO (IT) | 2016-08-09 | — | — | US | claimed |
| US-20150183891-A1 | METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS | UNIVERSITA' DEGLI STUDI DI PALERMO (IT) | 2015-07-02 | — | — | US | claimed |
| US-8858999-B2 | Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels thereof | UNIVERSITA' DEGLI STUDI DI PALERMO (IT) | 2014-10-14 | — | — | US | claimed |
| EP-2370474-B1 | METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS THEREOF | UNIV PALERMO (IT) | 2012-10-24 | — | — | EP | claimed |
| EP-2370474-A1 | METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS THEREOF | Universita' degli Studi di Palermo (IT) | 2011-10-05 | — | — | EP | claimed |
| US-20110236486-A1 | METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS THEREOF | UNIVERSITA' DEGLI STUDI DI PALERMO (IT) | 2011-09-29 | — | — | US | claimed |
| CN-101972672-A | S-acylation L-cysteine and application of salt thereof as catalyst for asymmetrical organic synthesis reaction | CHONGQING YIPAIYIN CHEMICAL PRODUCTS CO LTD | 2011-02-16 | — | — | CN | claimed |
| WO-2010061005-A1 | METHOD TO PRODUCE HYALURONIC ACID FUNCTIONALIZED DERIVATIVES AND FORMATION OF HYDROGELS THEREOF | UNIVERSITA' DEGLI STUDI DI PALERMO (IT) | 2010-06-03 | — | — | WO | claimed |
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | WEINER, CARL P | 2009-12-24 | — | — | US | claimed |
| CN-101027092-A | Non-absorbent and absorbent articles for inhibiting the production of exoproteins | KIMBERLY CLARK CO (US) | 2007-08-29 | — | — | CN | claimed |
| EP-1793871-A2 | NON-ABSORBENT AND ABSORBENT ARTICLES FOR INHIBITING THE PRODUCTION OF EXOPROTEINS | Kimberly-Clark Worldwide, Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006038980-A2 | NON-ABSORBENT AND ABSORBENT ARTICLES FOR INHIBITING THE PRODUCTION OF EXOPROTEINS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| US-20060067991-A1 | Non-absorbent articles for inhibiting the production of exoproteins | KIMBERLY-CLARK WORLDWIDE, INC. | 2006-03-30 | — | — | US | claimed |
| US-20060067990-A1 | Absorbent articles for inhibiting the production of exoproteins | KIMBERLY-CLARK WORLDWIDE, INC. | 2006-03-30 | — | — | US | claimed |
| EP-1379214-A1 | HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING SAME | L'OREAL, S.A. (FR) | 2004-01-14 | — | — | EP | claimed |
| US-20020159962-A1 | Hair relaxer compositions comprising at least one hydroxide compound and at least one activating agent, and methods of using the same | L'OREAL S.A. (FR) | 2002-10-31 | — | — | US | claimed |
| WO-2002067875-A1 | HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING THE SAME | L'OREAL S.A. (FR) | 2002-09-06 | — | — | WO | claimed |
| WO-2025061827-A1 | KIT FOR THE RECONSTITUTION OF A CELL-FREE BIOMEDICAL DEVICE FOR USE IN REGENERATIVE MEDICINE, BIOMEDICAL DEVICE THUS RECONSTITUTED AND RELATED SYNTHESIS PROCESS | FONDAZIONE RI.MED (IT) | 2025-03-27 | — | — | WO | disclosed |
| EP-0112720-A2 | Conjugate having cytotoxicity and process for the preparation thereof | TEIJIN LIMITED (JP) | 1984-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067990-A1 | Absorbent articles for inhibiting the production of exoproteins | SLC43A1, MRPL21, SLC7A5 | CA2 1846/4885CA1 3676/4885CTRB1 583/4885 |
| US-20060067991-A1 | Non-absorbent articles for inhibiting the production of exoproteins | SLC43A1, MRPL21, SLC7A5 | CA2 1875/4885CA1 3741/4885CTRB1 392/4885 |
| US-20090318454-A1 | NOVEL ANTIOXIDANTS AND METHODS OF TREATMENT | GPX1, SOD1, GPX4 | CA2 2012/4885CA1 1526/4885CTRB1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.